Characteristic | All cases | HDAC 3 low (IRS 0–4) | HDAC 3 intermediate (IRS 6–8) | HDAC 3 high (IRS 9–12) | P-value χ 2-test for trends |
---|---|---|---|---|---|
All cases | 224 (100%) | 80 (35.7%) | 73 (32.6%) | 71 (31.6%) | -- |
Histological type | 0.34 | ||||
Ductal carcinoma/Other | 185 (100%) | 69 (37.2%) | 58 (31.4%) | 58 (31.4%) | |
Lobular carcinoma | 35 (100%) | 10 (28.6%) | 12 (34.3%) | 13 (37.1%) | |
Histological grade | <0.001* | ||||
G1 | 63 (100%) | 32 (50.8%) | 19 (30.2%) | 12 (19%) | |
G2 | 101 (100%) | 33 (32.7%) | 35 (34.6%) | 33 (32.7%) | |
G3 | 56 (100%) | 14 (25%) | 16 (28.6%) | 26 (46.4%) | |
Nodal status | 0.61 | ||||
negative | 133 (100%) | 51 (38.3%) | 39 (29.3%) | 43 (32.4%) | |
positive | 78 (100%) | 26 (33.3%) | 26 (33.3%) | 26 (33.3%) | |
pT-Stage | 0.55 | ||||
pT1 | 119 (100%) | 43 (36.1%) | 37 (31.1%) | 39 (32.8%) | |
pT2/pT3 | 87 (100%) | 28 (32.2%) | 29 (33.3%) | 30 (34.5%) | |
pT4 | 13 (100%) | 7 (53.8%) | 4 (30.8%) | 2 (15.4%) | |
Hormone receptor status | 0.04* | ||||
Hormone receptor positive | 176 (100%) | 65 (36.9%) | 63 (35.8%) | 48 (27.3%) | |
Hormone receptor negative | 43 (100%) | 14 (32.6%) | 7 (16.3%) | 22 (51.2%) | |
HER2 status | 0.12 | ||||
negative | 191 (100%) | 71 (37.2%) | 63 (35.8%) | 48 (27.3%) | |
positive | 25 (100%) | 8 (32%) | 4 (16%) | 13 (52%) |